Komori
Other Disclosures1783Fantasista Co.,Ltd.Real Estate

Notice Regarding the Launch of the Children’s Supplement Brand "ぞうさんのおみせ" and the Release of New Products

A consolidated subsidiary has launched the children's supplement brand “Elephant's Shop” and plans to release a new product under the brand shortly on Rakuten Ichiba. The retail price is ¥1,980, including consumption tax.

Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
1980
yen (tax included; selling price)
Wording
Conditional
How definitive the wording is.

Announced details

Elephant's Shop (children's supplement brand)Elephant's Shop children's lutein supplement
Applicable field (uses covered by this announcement)

Children's healthcare; maintaining children's health

Launch dateScheduled for release shortly (Rakuten Ichiba; preparations under way)
Relationship between the counterparty and the company
Fantasista Co.,Ltd.1783
Relationship with the Company

株式会社ハンドレッドイヤーズ is a consolidated subsidiary of the company

Location (as indicated in this announcement)

株式会社ハンドレッドイヤーズ headquarters: 8F Toka Building, 1-16-1 Ginza, Chuo-ku, Tokyo

Offering price

¥1,980 (including consumption tax)

Impact on Business Performance

The impact on consolidated results for the fiscal year ending September 2026 is expected to be minor

The company does not address Contract Value.

Announced details
ItemDetails
Names of Products / Services CoveredElephant's Shop (children's supplement brand), Elephant's Shop children's lutein supplement
Relationship with the Company株式会社ハンドレッドイヤーズ is a consolidated subsidiary of the company
Offering price¥1,980 (including consumption tax)
Launch dateScheduled for release shortly (Rakuten Ichiba; preparations under way)
Applicable areaChildren's healthcare; maintaining children's health
Location株式会社ハンドレッドイヤーズ headquarters: 8F Toka Building, 1-16-1 Ginza, Chuo-ku, Tokyo
Impact on Business PerformanceThe impact on consolidated results for the fiscal year ending September 2026 is expected to be minor
Items this document does not state (11)
CounterpartyCounterparty overviewContract ValueContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historySource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company is entering the children's healthcare market against a backdrop of increased opportunities for children to use digital devices as a result of initiatives such as the GIGA School Program, as well as growing parental interest in children's lifestyles and health.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Launch of the Children’s Supplement Brand "ぞうさんのおみせ" and the Release of New Products | Fantasista Co.,Ltd. (1783) timely disclosure | Komori